Short Interest in Exicure, Inc. (NASDAQ:XCUR) Decreases By 74.8%

Exicure, Inc. (NASDAQ:XCUR) saw a large drop in short interest in September. As of September 15th, there was short interest totalling 32,600 shares, a drop of 74.8% from the August 31st total of 129,500 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is currently 0.0 days. Currently, 4.9% of the shares of the stock are short sold.

Insider Buying and Selling at Exicure

In other Exicure news, major shareholder Co. Ltd. Dgp purchased 237,223 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were purchased at an average cost of $3.00 per share, with a total value of $711,669.00. Following the completion of the purchase, the insider now owns 849,223 shares in the company, valued at approximately $2,547,669. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 3.90% of the stock is currently owned by insiders.

Exicure Stock Performance

NASDAQ XCUR opened at $3.81 on Friday. The stock’s fifty day moving average is $1.01 and its two-hundred day moving average is $0.41. The firm has a market capitalization of $6.59 million, a P/E ratio of -2.51 and a beta of 1.24. Exicure has a fifty-two week low of $1.44 and a fifty-two week high of $6.00.

Exicure (NASDAQ:XCUR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.01) earnings per share for the quarter.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.